ALFA Finder| Revenue growth | 39.7% YoY in INR terms. |
|---|---|
| Margins | EBITDA margin at 16.9%; aiming to restore to historical levels. |
| Order book | Active client base expanded to 105; 14 sequential additions. |
| Demand visibility | Sustained demand across top 20 accounts; healthy Net Revenue Retention. |
| Management confidence | Strong start to FY27; strongest Q1 sequential growth in four years. |
Growth
Revenue grew 39.7% YoY in INR and 26.5% in USD; PAT grew 45.9% QoQ but remained flat YoY.
Outlook
Management expects operating leverage to improve and profitability to strengthen in H2 FY27 as investments mature.
Risks
PAT margin compression (10.9% vs 15.3% YoY); high dependence on Biopharma sector (91.6% of revenue).
Last quarter's promises, checked
Delivered
- Guided Q4 revenue ₹10,000M → delivered ₹10,000M (= BEAT)
- Guided FY26 revenue >₹3,500 Cr → delivered ₹3,510.5 Cr (= BEAT)
- Guided 12.5% dividend increase → delivered ₹2.25/share (= BEAT)
Partly delivered
- Guided EBITDA margin recovery in FY27 → delivered 16.9% in Q1 (= PARTIAL)
- Guided debtor days 60-70 → delivered 63 days (= BEAT)
Missed
- Guided PAT growth → delivered 1.4% decline YoY (= MISS)
Investor Presentation filed with BSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹616.00
- Market cap
- ₹14,841 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.1×Sector 54.5×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 12.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Earnings Call Transcript: Key Takeaways
Strong top-line growth driven by pharma digital transformation, but near-term margins are compressed by annual wage hikes and mutual fund mark-downs.
Indegene Management Change
Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Indegene Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 11,223M (+39.5% YoY, +5.6% QoQ), EBITDA margin 16.7%, PAT INR 1,123M (+10% YoY). BioPharm integration ahead of plan.
Indegene Results Update
Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.
Indegene Q2 FY27 Results: Net Profit ₹112.3 Cr, Up 10.0% YoY
Indegene Ltd reported revenue from operations of ₹1,122 Cr (+39.6% YoY) and net profit of ₹112.3 Cr (+10.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹112.3 Cr · +10.0% YoY